Showing 1716 results
-
Ad hoc release /Novartis showcases unique profile with therapeutic area breadth and depth, exposure to cutting edge platforms and diversification of revenues in terms of assets and geographies Key growth…
-
Press release /With more than 140 abstracts, Novartis continues its leadership in hematology innovation Data for MBG453, an innovative anti-TIM-3 immunotherapy, with decitabine on preliminary response rates in…
-
Press release /Proposed acquisition builds on existing agreement with CellforCure for contract manufacturing of Novartis leading CAR-T cell therapy Kymriah® (tisagenlecleucel) and recent successful completion of…
-
Press release /Deal includes reSET®, cleared by FDA for treatment of patients with Substance Use Disorder, and reSET-O(TM), potential treatment pending FDA clearance for patients with Opioid Use Disorder treated…
-
Press release /Tabrecta demonstrated an overall response rate of 68% and 41% in treatment-naive and previously treated non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping (METex14) respectively…
-
Ad hoc release /Basel, December 5, 2019 — Novartis AG (NYSE: NVS) (“Novartis”) today announced that its indirect wholly-owned subsidiary, Medusa Merger Corporation, a Delaware corporation (“Purchaser”), has…
-
Story /Improving the patient experience and removing potential barriers to clinical trial participation
-
Press release /Glatopa® 40 mg/mL is a fully substitutable, AP-rated generic version of Copaxone®* (glatiramer acetate injection) 40 mg/mL Glatopa 40 mg/mL, along with Glatopa® 20 mg/mL, which was launched…
-
Press release /Phase II study efficacy data showed overall response rate of 72.0% and 39.1%, respectively, in treatment-naive and previously treated patients with advanced MET exon-14 skipping mutated non-small…
-
Press release /New Cosentyx® (secukinumab) label to include dosing flexibility up to 300 mg, based on clinical response, and 24-week structural data with subcutaneous (sc) regimens[1] Cosentyx inhibits…